Chemotherapy, Immunotherapy, Non Small Cell Lung Cancer, Tumour, Residual
Conditions
Brief summary
This is a real-world study with the largest sample size investigating the pathological tumor and lymph node responses to neoadjuvant immunochemotherapy in non-small cell lung cancer to date. Patients with initially unresectable NSCLC underwent immunochemotherapy and response to treatment was assessed after every two treatment cycles. Clinicopathologic features of patients including epidemiological data, clinical manifestations, operation strategies, pathological findings, and prognostic information were recorded and evaluated.
Interventions
DRUGTiming of drug administration
The effect of drug administration timing on tumor and lymph node responses was observed.
Sponsors
Guangdong Provincial People's Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with stage III NSCLC who received neoadjuvant immunochemotherapy. * early-stage NSCLC patients who were initially unresectable. * 18 years of age or older. * Karnofsky performance status (KPS) score of 100 or 90.
Exclusion criteria
* Patients with stage IV NSCLC * Patients with known ALK translocations or EGFR mutations. * Karnofsky performance status (KPS) score \<90.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival | At least one year | the time from diagnosis to any progression of disease precluding surgery, progression or recurrence of disease after surgery or death from any cause. |
Countries
China
Outcome results
None listed